![Prior to ASCO, most interest in Keytruda in mCRPC and aNSCLC](https://breakingdata.com/wp-content/uploads/2018/09/Insight-1.png)
Prior to ASCO, Oncologists Were Interested in KEYTRUDA® for Metastatic CRPC and Advanced NSCLC
Prior to ASCO, Breaking Data asked 30 oncologists to rate each abstract in terms of their level of interest. The chart depicts pre-ASCO oncologist interest in the data…